Olanzapine-induced changes in glucose metabolism are independent of the melanin-concentrating hormone system

Psychoneuroendocrinology

Volumn 38, Issue 11, 2013, Pages 2640-2646

  Girault, Elodie M ^a   Toonen, Pim W ^c   Eggels, Leslie ^b   Foppen, Ewout ^a,b   Ackermans, Mariëtte T ^b   La Fleur, Susanne E ^b   Fliers, Eric ^b   Kalsbeek, Andries ^a,b  

^a NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Atypical antipsychotics; Body weight gain; Corticosterone; Endogenous glucose production; Glucose metabolism; Insulin resistance; MCH; Olanzapine; PMCH KO; Schizophrenia

Indexed keywords

CORTICOSTERONE; GLUCOSE; MELANIN CONCENTRATING HORMONE; OLANZAPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DISORDERS OF CARBOHYDRATE METABOLISM; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HYPERGLYCEMIA; INSULIN RESISTANCE; MELANIN CONCENTRATING HORMONE GENE; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; WILD TYPE;

ATYPICAL ANTIPSYCHOTICS; BODY WEIGHT GAIN; CORTICOSTERONE; ENDOGENOUS GLUCOSE PRODUCTION; GLUCOSE METABOLISM; INSULIN RESISTANCE; MCH; OLANZAPINE; PMCH KO; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; CORTICOSTERONE; GENE KNOCKOUT TECHNIQUES; GENOTYPE; GLUCOSE METABOLISM DISORDERS; HYPOTHALAMIC HORMONES; INSULIN; MALE; MELANINS; PITUITARY HORMONES; RATS;

EID: 84886097249     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2013.06.021     Document Type: Article

References (42)

1. Ackermans M.T., Pereira Arias A.M., Bisschop P.H., Endert E., Sauerwein H.P., Romijn J.A. The quantification of gluconeogenesis in healthy men by (2)H2O and [2-(13)C]glycerol yields different results: rates of gluconeogenesis in healthy men measured with (2)H2O are higher than those measured with [2-(13)C]glycerol. J. Clin. Endocrinol. Metab. 2001, 86:2220-2226.
2. Albaugh V.L., Judson J.G., She P., Lang C.H., Maresca K.P., Joyal J.L., Lynch C.J. Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis. Mol. Psychiatry 2010.
3. Attademo A.M., Sanchez-Borzone M., Lasaga M., Celis M.E. Intracerebroventricular injection of neuropeptide EI increases serum LH in male and female rats. Peptides 2004, 25:1995-1999.
4. Bittencourt J.C., Presse F., Arias C., Peto C., Vaughan J., Nahon J.L., Vale W., Sawchenko P.E. The melanin-concentrating hormone system of the rat brain: an immuno- and hybridization histochemical characterization. J Comp Neurol. 1992, 319:218-245.
5. Chagnon Y.C., Bureau A., Gendron D., Bouchard R.H., Merette C., Roy M.A., Maziade M. Possible association of the pro-melanin-concentrating hormone gene with a greater body mass index as a side effect of the antipsychotic olanzapine. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007, 144B:1063-1069.
6. Chagnon Y.C., Merette C., Bouchard R.H., Emond C., Roy M.A., Maziade M. A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses. Mol. Psychiatry 2004, 9:1067-1074.
7. Chiu C.C., Chen C.H., Chen B.Y., Yu S.H., Lu M.L. The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34:866-870.
8. Cooper G.D., Pickavance L.C., Wilding J.P., Halford J.C., Goudie A.J. A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology (Berlin) 2005, 181:80-89.
9. Gaston S., Gargiulo P.A., Bregonzio C., Baiardi G. Intra-amygdaloid microinjection of neuropeptide glutamic acid-isoleucine induces anxiety-like behavior. Neuroreport 2011, 22:83-87.
10. Girault E.M., Alkemade A., Foppen E., Ackermans M.T., Fliers E., Kalsbeek A. Acute peripheral but not central administration of olanzapine induces hyperglycemia associated with hepatic and extra-hepatic insulin resistance. PLoS One. 2012, 7:e43244.
11. Girault E.M., Foppen E., Ackermans M.T., Fliers E., Kalsbeek A. Central administration of an orexin receptor 1 antagonist prevents the stimulatory effect of Olanzapine on endogenous glucose production. Brain Res. 2013, in press.
12. Guesdon B., Denis R.G., Richard D. Additive effects of olanzapine and melanin-concentrating hormone agonism on energy balance. Behav. Brain Res. 2010, 207:14-20.
13. Hervieu G., Nahon J.L. Pro-melanin concentrating hormone messenger ribonucleic acid and peptides expression in peripheral tissues of the rat. Neuroendocrinology 1995, 61:348-364.
14. Kapur S., VanderSpek S.C., Brownlee B.A., Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J. Pharmacol Exp. Ther. 2003, 305:625-631.
15. Liebig M., Gossel M., Pratt J., Black M., Haschke G., Elvert R., Juretschke H.P., Neumann-Haefelin C., Kramer W., Herling A.W. Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625. Obesity (Silver Spring) 2010, 18:1952-1958.
16. Ludwig D.S., Tritos N.A., Mastaitis J.W., Kulkarni R., Kokkotou E., Elmquist J., Lowell B., Flier J.S., Maratos-Flier E. Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. J. Clin. Invest. 2001, 107:379-386.
17. Marsh D.J., Weingarth D.T., Novi D.E., Chen H.Y., Trumbauer M.E., Chen A.S., Guan X.M., Jiang M.M., Feng Y., Camacho R.E., Shen Z., Frazier E.G., Yu H., Metzger J.M., Kuca S.J., Shearman L.P., Gopal-Truter S., MacNeil D.J., Strack A.M., MacIntyre D.E., Van der Ploeg L.H., Qian S. Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism. Proc. Natl. Acad. Sci. USA 2002, 99:3240-3245.
18. Minet-Ringuet J., Even P.C., Goubern M., Tome D., de B.R. Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration. Appetite 2006, 46:254-262.
19. Mul J.D., Yi C.X., van den Berg S.A., Ruiter M., Toonen P.W., van der Elst M.C., Voshol P.J., Ellenbroek B.A., Kalsbeek A., la Fleur S.E., Cuppen E. Pmch expression during early development is critical for normal energy homeostasis. Am. J. Physiol. Endocrinol. Metab. 2010, 298:E477-E488.
20. Pissios P., Ozcan U., Kokkotou E., Okada T., Liew C.W., Liu S., Peters J.N., Dahlgren G., Karamchandani J., Kudva Y.C., Kurpad A.J., Kennedy R.T., Maratos-Flier E., Kulkarni R.N. Melanin concentrating hormone is a novel regulator of islet function and growth. Diabetes 2007, 56:311-319.
21. Qu D., Ludwig D.S., Gammeltoft S., Piper M., Pelleymounter M.A., Cullen M.J., Mathes W.F., Przypek R., Kanarek R., Maratos-Flier E. A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature 1996, 380:243-247.
22. Rao Y., Lu M., Ge F., Marsh D.J., Qian S., Wang A.H., Picciotto M.R., Gao X.B. Regulation of synaptic efficacy in hypocretin/orexin-containing neurons by melanin concentrating hormone in the lateral hypothalamus. J. Neurosci. 2008, 28:9101-9110.
23. Sacher J., Mossaheb N., Spindelegger C., Klein N., Geiss-Granadia T., Sauermann R., Lackner E., Joukhadar C., Muller M., Kasper S. Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers. Neuropsychopharmacology 2008, 33:1633-1641.
24. Sailer A.W., Sano H., Zeng Z., McDonald T.P., Pan J., Pong S.S., Feighner S.D., Tan C.P., Fukami T., Iwaasa H., Hreniuk D.L., Morin N.R., Sadowski S.J., Ito M., Ito M., Bansal A., Ky B., Figueroa D.J., Jiang Q., Austin C.P., MacNeil D.J., Ishihara A., Ihara M., Kanatani A., Van der Ploeg L.H., Howard A.D., Liu Q. Identification and characterization of a second melanin-concentrating hormone receptor, MCH-2R. Proc. Natl. Acad. Sci. USA 2001, 98:7564-7569.
25. Saito Y., Maruyama K. Identification of melanin-concentrating hormone receptor and its impact on drug discovery. J. Exp. Zool. A Comp. Exp. Biol. 2006, 305:761-768.
26. Sanchez M., Baker B.I., Celis M. Melanin-concentrating hormone (MCH) antagonizes the effects of alpha-MSH and neuropeptide E-I on grooming and locomotor activities in the rat. Peptides 1997, 18:393-396.
27. Sanchez M.S., Salvatierra N.A., Vettori G., Celis M.E. Effect of neuropeptide-EI on the binding of [3H]SCH 23390 to the dopamine D1 receptor in rat striatal membranes. Neurochem. Res. 2001, 26:533-537.
28. Shearman L.P., Camacho R.E., Sloan S.D., Zhou D., Bednarek M.A., Hreniuk D.L., Feighner S.D., Tan C.P., Howard A.D., Van der Ploeg L.H., MacIntyre D.E., Hickey G.J., Strack A.M. Chronic MCH-1 receptor modulation alters appetite, body weight and adiposity in rats. Eur. J. Pharmacol. 2003, 475:37-47.
29. Shimada M., Tritos N.A., Lowell B.B., Flier J.S., Maratos-Flier E. Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature 1998, 396:670-674.
30. Shobo M., Yamada H., Koakutsu A., Hamada N., Fujii M., Harada K., Ni K., Matsuoka N. Chronic treatment with olanzapine via a novel infusion pump induces adiposity in male rats. Life Sci. 2011, 88:761-765.
31. Sita L.V., Elias C.F., Bittencourt J.C. Connectivity pattern suggests that incerto-hypothalamic area belongs to the medial hypothalamic system. Neuroscience 2007, 148:949-969.
32. Skofitsch G., Jacobowitz D.M., Zamir N. Immunohistochemical localization of a melanin concentrating hormone-like peptide in the rat brain. Brain Res. Bull. 1985, 15:635-649.
33. Smith G.C., Vickers M.H., Shepherd P.R. Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat. Arch. Physiol. Biochem. 2011, 117:241-249.
34. Smits B.M., Mudde J.B., van de Belt J., Verheul M., Olivier J., Homberg J., Guryev V., Cools A.R., Ellenbroek B.A., Plasterk R.H., Cuppen E. Generation of gene knockouts and mutant models in the laboratory rat by ENU-driven target-selected mutagenesis. Pharmacogenet. Genomics 2006, 16:159-169.
35. Steele R. Influences of glucose loading and of injected insulin on hepatic glucose output. Ann. NY Acad. Sci. 1959, 82:420-430.
36. Stefanidis A., Verty A.N., Allen A.M., Owens N.C., Cowley M.A., Oldfield B.J. The role of thermogenesis in antipsychotic drug-induced weight gain. Obesity (Silver Spring) 2009, 17:16-24.
37. Tadayyon M., Welters H.J., Haynes A.C., Cluderay J.E., Hervieu G. Expression of melanin-concentrating hormone receptors in insulin-producing cells: MCH stimulates insulin release in RINm5F and CRI-G1 cell-lines. Biochem. Biophys. Res. Commun. 2000, 275:709-712.
38. Tsuneki H., Wada T., Sasaoka T. Role of orexin in the regulation of glucose homeostasis. Acta. Physiol. (Oxf) 2010, 198:335-348.
39. van der Zwaal E.M., Luijendijk M.C., Adan R.A., la Fleur S.E. Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution. Eur. J. Pharmacol. 2008, 585:130-136.
40. van der Zwaal E.M., Luijendijk M.C., Evers S.S., la Fleur S.E., Adan R.A. Olanzapine affects locomotor activity and meal size in male rats. Pharmacol. Biochem. Behav. 2010, 97:130-137.
41. van B.R., Toonen P.W., van Roekel H.S., Verheul M., Smits B.M., Korving J., de B.A., Cuppen E. Lack of DNA mismatch repair protein MSH6 in the rat results in hereditary non-polyposis colorectal cancer-like tumorigenesis. Carcinogenesis 2008, 29:1290-1297.
42. Yi C.X., Serlie M.J., Ackermans M.T., Foppen E., Buijs R.M., Sauerwein H.P., Fliers E., Kalsbeek A. A major role for perifornical orexin neurons in the control of glucose metabolism in rats. Diabetes 2009, 58:1998-2005.